Skip to main content
. 2023 Dec 21;14:1329266. doi: 10.3389/fphar.2023.1329266

TABLE 1.

Demographic and clinical characteristics of patients with liver fibrosis before antiviral therapy.

Group Regression group (n = 30) Non-regression group (n = 30) Statistics p-value
Male/female, n 20/10 20/10
Age (y) 43 ± 7.33 42.67 ± 9.65 0.151 0.248
BMI 23.54 ± 2.58 24.38 ± 2.95 −1.164 0.881
ALT (IU/L) 39 (26, 63.05) 40 (24.75, 60.35) −0.126 0.9
AST (IU/L) 38.5 (29, 49.1) 50.45 ± 27 −0.547 0.584
Alb (g/L) 44.25 (41.03, 47) 41.5 (37.13, 45.23) 1.382 0.167
TBIL (μmol/L) 12.95 (9.25, 18.51) 13.35 (10.13, 18.2) −0.266 0.79
GGT (IU/L) 77.9 ± 68.19 75.07 ± 52.78 0.18 0.858
ALP (IU/L) 100.17 ± 25.77 92.81 ± 33.9 0.918 0.363
Cr (μmol/L) 70.73 ± 16.03 70.8 ± 20.38 −0.014 0.989
WBC (×109/L) 5.35 ± 1.8 4.66 ± 1.2 1.713 0.093
HGB (g/L) 141 (137, 151) 140 (131.5, 148.5) −0.845 0.398
PLT (×109/L) 128.37 ± 54.58 104.89 ± 35.73 1.763 0.06
PT (s) 12.53 ± 1.49 13.55 ± 1.69 −0.044 0.965
TC (mmol/L) 4.16 ± 0.94 4.15 ± 1.04 0.026 0.979
TG (mmol/L) 1.14 ± 0.45 0.94 (0.67, 1.16) 1.678 0.093
HDL-CH (mmol/L) 1.3 ± 0.38 1.42 ± 0.33 −1.292 0.201
LDL-CH (mmol/L) 2.56 ± 0.89 2.41 ± 0.95 0.62 0.538
Blood glucose (mmol/L) 5.16 ± 0.85 5.26 ± 7.9 −0.427 0.672
AFP (μg/L) 6.98 (3.48, 20.33) 8.48 (3.88, 22.56) −0.118 0.906
Positive HBeAg, n, % 13 (43.33) 14 (46.67) 0.067 0.795
Log10 HBV DNA (IU/mL) 4.84 ± 2.17 4.46 ± 1.85 0.326 0.471
Ishak score 0 1
F5, n, % 14 (46.67) 14 (46.67)
F6, n, % 16 (53.33) 16 (53.33)

Mean values are provided with SD, and medians are provided with quartiles (Q1, Q3).

Annotations: BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Alb, Albumin; TBIL, total bilirubin; GGT, γ-glutamyl transpeptidase; ALP, alkaline phosphatase; Cr, Creatinine; WBC, white blood cell; HGB, hemoglobin; PLT, platelet count; PT, prothrombin time; TC, total cholesterol; TG, triglyceride; HDL-CH, High-density lipoprotein cholesterol; LDL-CH, Low-density lipoprotein cholesterol; AFP, alpha fetoprotein.